Important News
Qurgen real-time updates on corporate news, industry trends and exciting events, witnessing every step of growth.
Important News
Suzhou Fuent Pharmaceutical Co., Ltd. received an additional investment of 50 million RMB, valuing the company at 625 million RMB after the supplementary investment.
Qurgen received FDA approval for the Phase I clinical trial IND (IND Number: 152226) for SON-DP, a transcription factor-based anti-tumor drug indicated for breast cancer, pancreatic cancer, ovarian cancer, and colorectal cancer.
Suzhou Fuent Pharmaceutical Co., Ltd. completed its first round of financing with RMB 125 million fully received, valuing the company at RMB 575 million post-investment.
Suzhou Fuent Pharmaceutical Co., Ltd. completed its first round of financing of 125 million RMB, led by the former general manager of a securities company, with a post-investment valuation of 575 million RMB.